

FIG. 1A



FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E





FIG. 1F



Patient #3_vMyx-hu-BiKE-GFP

FIG. 2A




FIG. 2B







FIG. 2C



Patient #3_vMyx-huBiKE-GFP gating on CD138⁺GFP⁻



Patient #4_vMyx-huBiKE-GFP

FIG. 4A




FIG. 4B





FIG. 4C






FIG. 4D

Patient #4_vMyx-huBiKE-GFP gating on CD138⁺GFP⁻

FIG. 5A





FIG. 5B






FIG. 6




FIG. 7




FIG. 8A




FIG. 8B

11 / 27




FIG. 8C




FIG. 8D




FIG. 9




FIG. 10




FIG. 11

14 / 27




FIG. 12




FIG. 13




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 15A




FIG. 15B




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B

MYXV Infection-killing efficiency of U266




FIG. 19

MYXV infection of CD138+ MM cells from primary MM patient BM samples




FIG. 20




FIG. 21




FIG. 22




FIG. 23A




FIG. 23B